| Factor Information | |
|---|---|
| Data ID | 823 |
| Factor | endothelin receptor antagonism (ERAs)(%) |
| Description | Comparison of basic clinical characteristics of 3 groups (iloprost positive group [IPG], iloprost negative group [ING], control group[CG]) |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | This study aimed at selecting effective biomarkers that could be used to assess the severity of CHD–PAH in patients and investigating the effect of iloprost at the level of biomarkers. |
| p Value | 0.04 |
| Conclusion | No differences were found in demographic and clinical characteristics of the enrolled patients between the three groups, except the administration of endothelin-1 receptor antagonists (P=0.04) and phosphodiesterase type-5 inhibitors (P=0.01) and other hemodynamic parameters (mRAP [P=0.03], PASP [P<0.01], and pulmonary vascular resistance [PVR] [P=0.02]). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 28608969 |
| Year | 2017 |
| Title | Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension. |
| Sample | ||
|---|---|---|
| Population | patients with CHD-PAH | |
| Source | blood | |
| Region | Shanghi, China | |
| Method | This prospective and observational study enrolled patients with CHD‐PAH. | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | iloprost positive group [IPG], iloprost negative group [ING](Treatment) | control group[CG](Control) |
| Number | 7(IPG)； 19(ING) | 5 |
| Age | IPG:48.57±12.56 years ING:49.52±14.43 years | CG: 51.42±6.14 years |
| Gender (Male: Female) | IPG (0:7) ING (5:14) | 1:4 |
| Marker Level | 1(14.3%)(IPG); 10(52.6%) (ING) | 0(0%) (CG) |
